ICOS: Added Heart Protection with NLA & AHA-Recommended Dyslipidemia Therapy

To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:

I acknowledge that my contact details may be used for this purpose*

IPE: Icosapent ethyl; AHA: American Heart Association (AHA) Science Advisory 2020; NLA: National Lipid Association (NLA) Scientific Statement 2019; T2DM: Type 2 diabetes; CAD: Coronary Artery Disease; TG: Triglyceride; CVD: Cardiovascular Diseases; CV: Cardiovascular; LDL-C: Low-density lipoprotein-cholesterol
GI-CO-A1-AQS-300040480-ELC-H24-1443
References:
1.	Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020;141(19):e779-e806.
2.	Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860-872.
*Prescribing information of ICOS, generated & latest modified on June 2023

Persistent CV Risk in Elevated Triglycerides Despite Statin Therapy: ICOS Solution

Mr. Basu’s case: a 54-year-old patient with diabetes, hypertension, and hyperlipidemia on statins, evaluated with...

Explore Ram's case to see how ICOS lowers first, subsequent, and total CV events in...

Explore Venu’s journey on statin therapy, where ICOS showed a 25% risk reduction in 5-Point...

Heart Meds Cut Risks, Spark GI Issues Now!

@media (max-width:992px) and (min-width:768px) {}         @media (max-width:767px)...